Abstract Number: 50 • 2017 Pediatric Rheumatology Symposium
Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients
Background/Purpose: Occurrence of psoriasis while on TNFα antagonists is a paradoxical effect of agents that treat psoriasis, and is described in larger cohorts of inflammatory…Abstract Number: 80 • 2017 Pediatric Rheumatology Symposium
Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
Background/Purpose: Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular…Abstract Number: 45 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…Abstract Number: 92 • 2016 ACR/ARHP Annual Meeting
Is Patient Support Program (PSP) Participation Associated with Longer Persistence and Greater Adherence Among New Users of Adalimumab?
Background/Purpose: In Israel, patients treated with adalimumab (ADA) can enroll in a patient support program (PSP) provided by AbbVie, which includes a home visit by…Abstract Number: 735 • 2016 ACR/ARHP Annual Meeting
Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on Response to Adalimumab (HUMIRA) in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course. The objective of…Abstract Number: 2638 • 2016 ACR/ARHP Annual Meeting
In Vitro Expansion of Treg By Adaimumab Predicts Clinical Response to Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Regulatory T cells (Treg) are potent suppressors of immune responses and are considered a pivotal element in resolving inflammation and autoimmunity. We have previously…Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting
Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…Abstract Number: 1101 • 2016 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell
Background/Purpose: TNF has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast (OC) development.…Abstract Number: 2639 • 2016 ACR/ARHP Annual Meeting
Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score
Background/Purpose: The multi-biomarker disease activity (MBDA) (Vectra® DA) score has been reported to predict disease relapses in patients with rheumatoid arthritis (RA) in sustained remission…Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…Abstract Number: 1245 • 2016 ACR/ARHP Annual Meeting
Comparison of Secukinumab Vs Adalimumab in a Cost per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthritis at 48 Weeks from the US Perspective
Comparison of Secukinumab vs Adalimumab in a cost per responder analysis based on a matching-adjusted indirect comparison of efficacy data for the treatment of psoriatic…Abstract Number: 2941 • 2016 ACR/ARHP Annual Meeting
Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Background/Purpose: In non-infectious no anterior uveitis, adalimumab (ADA) is the only biologic drug that has shown efficacy in phase III randomized, double blind studies,…Abstract Number: 416 • 2016 ACR/ARHP Annual Meeting
Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Approximately 10-15% of patients (pts) with juvenile idiopathic arthritis (JIA) experience comorbid uveitis. The objective of this study is to explore events of uveitis and…Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…Abstract Number: 2947 • 2016 ACR/ARHP Annual Meeting
Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients
Background/Purpose: Cystoid macular edema (CME) is the most serious complication of uveitis and the most common cause of blindness in uveitis. Our aim was…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 17
- Next Page »